1. Home
  2. ROIV vs CFR Comparison

ROIV vs CFR Comparison

Compare ROIV & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROIV
  • CFR
  • Stock Information
  • Founded
  • ROIV 2014
  • CFR 1868
  • Country
  • ROIV United Kingdom
  • CFR United States
  • Employees
  • ROIV N/A
  • CFR N/A
  • Industry
  • ROIV Biotechnology: Pharmaceutical Preparations
  • CFR Major Banks
  • Sector
  • ROIV Health Care
  • CFR Finance
  • Exchange
  • ROIV Nasdaq
  • CFR Nasdaq
  • Market Cap
  • ROIV 7.8B
  • CFR 7.9B
  • IPO Year
  • ROIV N/A
  • CFR N/A
  • Fundamental
  • Price
  • ROIV $10.99
  • CFR $126.93
  • Analyst Decision
  • ROIV Buy
  • CFR Hold
  • Analyst Count
  • ROIV 4
  • CFR 15
  • Target Price
  • ROIV $17.50
  • CFR $131.93
  • AVG Volume (30 Days)
  • ROIV 5.1M
  • CFR 346.6K
  • Earning Date
  • ROIV 05-29-2025
  • CFR 07-24-2025
  • Dividend Yield
  • ROIV N/A
  • CFR 3.15%
  • EPS Growth
  • ROIV N/A
  • CFR 7.71
  • EPS
  • ROIV N/A
  • CFR 9.11
  • Revenue
  • ROIV $29,053,000.00
  • CFR $2,038,108,000.00
  • Revenue This Year
  • ROIV N/A
  • CFR $13.57
  • Revenue Next Year
  • ROIV N/A
  • CFR $4.58
  • P/E Ratio
  • ROIV N/A
  • CFR $13.94
  • Revenue Growth
  • ROIV N/A
  • CFR 5.45
  • 52 Week Low
  • ROIV $8.73
  • CFR $94.09
  • 52 Week High
  • ROIV $13.06
  • CFR $147.64
  • Technical
  • Relative Strength Index (RSI)
  • ROIV 52.59
  • CFR 53.04
  • Support Level
  • ROIV $10.59
  • CFR $123.99
  • Resistance Level
  • ROIV $11.37
  • CFR $130.35
  • Average True Range (ATR)
  • ROIV 0.32
  • CFR 2.28
  • MACD
  • ROIV -0.01
  • CFR -0.40
  • Stochastic Oscillator
  • ROIV 52.23
  • CFR 37.48

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About CFR Cullen/Frost Bankers Inc.

Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.

Share on Social Networks: